Delineating an epigenetic continuum for initiation, transformation and progression to breast cancer.

Aberrant methylation of promoter CpG islands is a hallmark of human cancers and is an early event in carcinogenesis. We examined whether promoter hypermethylation contributes to the pathogenesis of benign breast lesions along a progression continuum to invasive breast cancer. The exploratory study cohort comprised 17 breast cancer patients with multiple benign and/or in situ lesions concurrently present with invasive carcinoma within a tumor biopsy. DNA from tumor tissue, normal breast epithelium when present, benign lesions (fibroadenoma, hyperplasia, papilloma, sclerosing adenosis, apocrine metaplasia, atypical lobular hyperplasia or atypical ductal hyperplasia), and in situ lesions of lobular carcinoma and ductal carcinoma were interrogated for promoter methylation status in 22 tumor suppressor genes using the multiplex ligation-dependent probe amplification assay (MS-MLPA). Methylation specific PCR was performed to confirm hypermethylation detected by MS-MLPA. Promoter methylation was detected in 11/22 tumor suppressor genes in 16/17 cases. Hypermethylation of RASSF1 was most frequent, present in 14/17 cases, followed by APC in 12/17, and GSTP1 in 9/17 cases with establishment of an epigenetic monocloncal progression continuum to invasive breast cancer. Hypermethylated promoter regions in normal breast epithelium, benign, and premalignant lesions within the same tumor biopsy implicate RASSF1, APC, GSTP1, TIMP3, CDKN2B, CDKN2A, ESR1, CDH13, RARB, CASP8, and TP73 as early events. DNA hypermethylation underlies thepathogenesis of step-wise transformation along a monoclonal continuum from normal to preneoplasia to invasive breast cancer.

Introduction

Progression from a pre-malignant lesion to malignancy is associated with cytogenetic and molecular genetic aberrations [1-3]. Benign breast lesions (BBD) with clinically significant pre-malignant potential include atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), and lobular carcinoma in situ (LCIS) [4] whereas ductal carcinoma in situ (DCIS) is considered a pre-invasive malignant lesion [5].

Epigenetics is the regulation of changes in gene expression by mechanisms that do not involve changes in DNA sequence. Establishment and maintenance of epigenetic control (gene silencing) has several aspects, which include promoter region hypermethylation, methyl-binding proteins, DNA methyltransferases, histone deacetylases and chromatin state. Epigenetic alterations, in particular promoter hypermethylation, are proving to be consistent and early events in neoplastic progression [6-9]. Such alterations are thought to contribute to the neoplastic process by transcriptional silencing of tumor suppressor gene expression and by increasing the rate of genetic mutation [10,11].

The potential that aberrant methylation may be pharmacologically reversible offers additional treatment opportunities for breast cancer. We examined whether promoter hypermethylation contributes to the pathogenesis of benign and premalignant breast lesions along a progression continuum to invasive breast cancer.

Results and Discussion

For the 17 breast cancer cases, the number of multiple lesions within a breast cancer biopsy ranged from 2–7. DNA was obtained from 71 lesions, and included 15 normal, 16 benign, 11 carcinoma-in-situ (CIS) and 29 tumor lesions (from 68 tumor blocks), which were interrogated for methylation status using the Methylation-Specific Multiplex Ligation Dependent Probe Amplification (MS-MLPA) assay (Table 1).

Table 1.

Cases with a methylation continuum.

Case 1	4/N	3/DCIS	2/IDC
		APC*	APC*
		GSTP1	RASSF1*
Case 2	5/N	4/ALH	1/LCIS	3/ILC	5/ILC
		APC†	APC*	APC*	APC*
		RASSF1†	RASSF1*	RASSF1*	RASSF1*
			RARB	RARB	RARB
			CASP8	CASP8	CASP8
			CDH13	CDH13
					GSTP1†
Case 3	11/N	3/H	5/Pap	6/IDC	10/IDC
	APC†	APC†	APC†	APC*	APC*
	RASSF1†	RASSF1†		RASSF1*	RASSF1*
		GSTP1†		GSTP1†	GSTP1*
	CDKN2B				CDH13
	ESR1				TP73
Case 5	6/N	5/FA	5/Pap	2/IDC	8/IDC
			APC†	APC†	APC†
	RASSF1†	RASSF1*	RASSF1*	RASSF1†
	GSTP1	GSTP1	GSTP1		GSTP1
	TP73				TP73
		CDKN2A			ESR1
Case 7	7/N	2/ALH	4/ILC	5/ILC
		GSTP1	GSTP1
	TIMP3	TIMP3
		CDKN2B	CDKN2B
		ESR1	ESR1
			RASSF1
Case 9	1/N	4/DCIS	2/IDC	3/IDC
		APC	APC	APC
		RASSF1	RASSF1	RASSF1
			RARB	RARB
				CDKN2B
Case 11	10/N	1/DCIS	4/DCIS	3/IDC	8/IDC
	RASSF1	RASSF1	RASSF1	RASSF1	RASSF1
	TIMP3
Case 15		4/DCIS	10/IDC
		APC	APC
		TIMP3	TIMP3
		CDKN2A	CDKN2A
		GSTP1	RARB
Case 18	3/N	4/DCIS	3/IDC	4/IDC
		APC	APC	APC
		RASSF1	RASSF1	RASSF1
		CDH13	CDH13	CDH13
			GSTP1	GSTP1
Case 19		8/DCIS	5/IDC
		RASSF1	RASSF1
			APC
			TIMP3

M = methylated by MS-MLPA; M* = MS-MLPA methylation confirmed by MSP; M = methylation detected by MSP only; N = normal; FA = fibroadenoma; H = hyperplasia; Pap = papilloma; AM = apocrine metaplasia; AM = apocrine metaplasia; ADH = atypical ductal hyperplasia; ALH = atypical lobular hyperplasia; SA = sclerosing adenosis; LCIS = lobular carcinoma in situ; DCIS = ductal carcinoma in situ; IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; number refers to tissue block

The MS-MLPA assay was performed in all cases and MS-MLPA results were confirmed by Methylation Specific PCR (MSP) for those cases 1, 2, 3, and 5 with sufficient DNA for bisulfate conversion (Table 1).

The Methylation-Specific Multiplex Ligation Dependent Probe Amplification (MS-MLPA) Assay results

Promoter methylation was detected in 11/22 tumor suppressor genes in 16/17 cases. DNA hypermethylation of RASSF1 was most frequently present in 14/17 cases with establishment of an epigenetic progression continuum to invasive breast cancer in 7 of the 14 cases, and an early transformation event along a progression continuum from normal to benign to breast cancer in Cases 3 and 5, benign (ALH) to LCIS to tumor in Case 2 (Figure 1 C-E), and normal to DCIS to tumor in Case 11 (Table 1), respectively.

Figure 1.

Methylation-Specific Multiplex Ligation Dependent Probe Amplification (MS-MLPA) probe mix with HhaI enzyme in normal (control) DNA (A), and 4 biopsy specimens from Case 2 (B-E). Note methylation of APC, RARB, CASP8 and RASSF1 (both RASSF1 probes) in biopsies LCIS, tumor block #3 and tumor block # 5(C-E). (ALH – atypical lobular hyperplasia, LCIS – lobular carcinoma in situ, 3T – block 3 tumor and 5T – block 5 tumor).

Aberrant methylation of APC was noted in 12/17 cases with evidence of a progression continuum from normal to benign to invasive breast cancer in Case 3, benign to CIS to tumor in Case 2 (Figure 1C-1E), benign (papilloma) to tumor in Case 5, and DCIS to tumor in Cases 9, 15, and 18. Promoter hypermethylation of GSTP1 was observed in 9/17 cases with a progression continuum from normal to benign to invasive breast cancer in Case 5 and benign to invasive breast cancer in Cases 3 and 7. Methylation of TIMP3 in 4/17 cases linked normal and benign (ALH) lesions in Case 7, and DCIS and tumor lesions in Case 15. Aberrant methylation of CDKN2B and ESR1 in 4/17 cases, connected benign (ALH) and tumor lesions in Case 7. RARB, CDH13, CASP8, CDKN2A, were less frequently methylated, connecting CIS and tumor lesions in Case 2 (RARB, CDH13, CASP8), Case 18 (CDH13), and Case 15 (CDKN2A), Table 1.

Methylation Specific PCR (MS) Results

MSP for APC, GSTP1 and RASSF1, performed in Cases 1, 2, 3 and 5 (Table 1, Figure 2) confirmed aberrant methylation of APC detected by MS-MLPA for Case 1 (tumor), Case 2 (LCIS and tumor) and Case 3 (tumor block 6 and 10).

Figure 2.

Methylation Specific PCR (MSP) confirmation of aberrant methylation detected by MS-MLPA for RASSF1, APC, and GSTP1 for Case 2. (A) (RASSF1): Lanes 1-2: universal methylated and unmethylated controls. Lanes 3-10 span biopsies ALH – 5T. Note presence of methylated product in all biopsies. Lanes 11-12: negative control. (B) (APC): Lanes 1-2: universal methylated and unmethylated controls. Lanes 3-10 span biopsies ALH – 5T. Note presence of methylated product in all biopsies. Lanes 11-12: negative control. (C) (GSTP1): Lanes 1-2: universal methylated and unmethylated controls. Lanes 3-10 span biopsies ALH – 5T. Note presence of methylated product in biopsy 5T. Note absence of methylated product in biopsies ALH, LCIS and 3T. Lanes 11-12: negative control. (ALH – atypical lobular hyperplasia, LCIS – lobular carcinoma in situ, 3T – block 3 tumor and 5T – block 5 tumor).

In addition, MSP indicated aberrant methylation of APC in Case 1 (DCIS), Case 2 (ALH), Case 3 (normal, hyperplasia, and papilloma) and Case 5 (papilloma and tumor blocks 2 and 8), not detected by MS-MLPA (Table 1). MSP confirmed aberrant methylation of GSTP1 for Case 3 (tumor block 10) and lack of methylation in Case 5 tumor block 2, indicated by MS-MLPA. Additionally MSP identified GSTP1methylation in Case 2 (tumor block 5) and Case 3 (hyperplasia and tumor block 6), not detected by MS-MLPA. In Case 1 (DCIS) and Case 5 (normal, fibroadenoma, papilloma, and tumor block 8), MSP did not confirm MS-MLPA results for GSTP1. MSP of RASSF1 confirmed methylation detected by MS-MLPA for Case 1 (tumor), Case 2 (LCIS and tumor blocks 3 and 5), Case 3 (tumor blocks 6 and 10) and Case 5 (fibroadenoma and papilloma). Additional RASSF1 methylation was detected by MSP in Case 2 (ALH), Case 3 (normal and hyperplasia) and Case 5 (normal and tumor block 2).

Discussion

Epigenetic alterations produce heritable changes in gene expression without a change in the DNA coding sequence itself. Promoter region hypermethylation is known to be an early event in carcinogenesis [12-15]. The consequence of CpG island hypermethylation, especially for those islands associated with tumor suppressor gene promoters is the loss of tumor suppressor function, which contributes to tumorigenesis [2]. Clonal epigenetic alterations in benign and precancerous lesions may reflect biological peculiarities pertinent to tumor behavior.

Recurrent genomic aberrations are good indicators of genes that are causally associated with cancer development, transformation or progression. Our previous studies [14,15] have demonstrated that epigenetic events of DNA hypermethylation underlie the pathogenesis of benign sinonasal and laryngeal papillomas, including establishing a monoclonal origin for recurrent respiratory papillomas (RRP).

This study underscores promoter hypermethylation as an early event in the pathogenesis of breast cancer. Aberrant methylation in normal breast epithelium or benign lesions from four cases with progression implicated TP73, TIMP3, CDKN2B, ESR1, APC, GSTP1 and RASSF1 as early events. RASSF1 was most frequently methylated (14/17) cases followed by APC (12/17) cases and GSTP1 in 9/17 cases.

Methylation of RASSF1A and APC was reported to occur more frequently in benign samples from high risk women (determined by the Gail model) than in samples from low or intermediate risk women and was associated with epidemiologic markers of increased breast cancer risk [16]. RASSF1A methylation has been highly correlated with breast cancer risk, atypical cytology and benign breast disease requiring biopsy [17]. With respect to age, RASSF1A methylation has been noted to increase linearly between ages 32 and 55 [17]. RASSF1A influences the G1-S cell cycle checkpoint by regulating the level of cyclin D1 protein [18]. Methylation of RASSF1A leads to accumulation of cyclin D1 and may represent one mechanism for overriding cell cycle control under conditions of increased cell cycle pressure [16]. In microdissected breast tissue, Lehmann et al. [19] showed that the RASSF1A promoter was methylated in all epithelial hyperplasia and papilloma samples and in 83% of ductal carcinoma samples in situ, suggesting methylation of RASSF1A as a new marker for nonphysiological epithelial proliferation in the breast [19]. The study also found that in most cases of progression to invasive growth, epigenetic inactivation takes place before invasive growth develops, an observation confirmed by Pasquali et al. [20] who observed a progressive gain of methylation for RASSF1A from normal to hyperplasia acquiring statistical significance at CIS and invasive carcinoma.

Genetic and epigenetic alterations in APC (adenomatosis polyposis coli), a tumor suppressor gene originally implicated in colon cancer have been reported in other malignancies including breast cancers. A study of 76 breast cancer patients by Liu et al. [21] demonstrated that APC gene methylation correlated positively with TNM staging and negatively with protein expression suggesting a role in the development of breast cancer. Lee et al. [22] reported methylation of the APC promoter 1A in 42% of breast cancer aspiration fluid samples. They also found that APC was unmethylated in the aspiration fluids from normal breast tissue in patients with breast cancer and all benign breast disease patients in their cohort.

Glutathione S-transferase pi (GSTP1), at chromosome 11q13 [23], encodes for the glutathione S-transferase pi enzyme and plays an important role in detoxification and in susceptibility to cancer and other diseases. The pi-class of glutathione S-transferase enzymes has been associated with preneoplastic and neoplastic changes [24]. Inactivation of GSTP1 by promoter hypermethylation is characteristic of steroid related neoplasms such as breast, liver, and prostate cancers [24,25]. GSTP1 had increased levels of methylation in carcinoma in situ and invasive carcinoma samples [20] and MSP-based studies of human tissues demonstrated that GSTP1 promoter methylation is associated with gene inactivation in about 30% of primary breast carcinomas [24]. In our cohort, nine of 17 cases demonstrated aberrant methylation of GSTP1 and in three cases (Cases 3, 5, 7) a transformation continuum from benign to invasive carcinoma was evident.

In this study hypermethylation of TIMP3 was observed in normal and benign (ALH) lesions in Case 7 and in DCIS and tumor lesions in Case 15, implicating TIMP3 as an early event. TIMP3 belongs to a family of molecules that inhibit the proteolytic activity of matrix metalloproteinases [26,27]. TIMP3 is methylated in ∼30% of human breast cancer cell lines as well as ∼30% of primary breast tumors [28].

For cases with sufficient DNA, MSP for the most part confirmed promoter hypermethylation detected by MS-MLPA. MSP did not confirm MS-MLPA methylation of GSTP1 observed in several biopsies for Cases 1 and 5. While a distinct advantage of MS-MLPA is the ability to examine aberrant promoter methylation in multiple cancer genes in a single assay run, multiplex PCR of a large number of gene probes (22 unique genes) inherently encounters competitive amplification. In contrast, MSP examines only one gene at a time [29] and therefore, is more sensitive than MS-MLPA [29]. Additionally, MS-MLPA methylation and quantitation detection algorithms may miss hypermethylation events that do not reach the threshold for detection [2]. Regardless, MS-MLPA profiling of multiple genes for aberrantly methylated promoter regions is a valuable screening tool to determine frequency and pattern of gene inactivation in tumorigenesis. These epigenetic signatures, upon subsequent validation as diagnostic or prognostic epigenetic biomarkers, can become reduced to a more definitive candidate gene panel of only a few key genes. The latter would be amenable for increased detection sensitivity by a targeted 3 or 4 MS-MLPA gene probe panel or by MSP alone.

Tumor markers are often biochemical surrogates for tumor presence [30]. Serum carcinoembryonic antigen (CEA) concentrations are used clinically to monitor the tumor burden in patients with advanced breast cancer [31]. Given the lack of circulating tumor markers, particularly tumor associated antigens, and a dearth of reliable genetic markers for diagnosis of early breast cancer [30], methylation changes, which often precede apparent malignant changes, have potential utility in the early diagnosis of cancer [32].

Experimental Section

Patient Cohort

The study cohort comprised 17 breast cancer patients (Table 1) with concurrently present tumor, normal breast epithelium when present, and one or more benign lesions histologically characterized as fibroadenoma, hyperplasia, sclerosing adenosis, apocrine metaplasia, papilloma, atypical lobular hyperplasia (ALH), atypical ductal hyperplasia (ADH), or in situ lesions of lobular (LCIS) or ductal carcinoma (DCIS). Normal, benign, CIS, and tumor tissue were obtained from separate blocks when available and when present within the same tissue block, were microdissected to prevent contamination and separate out individual lesions for DNA extraction. Normal breast tissue controls for methylation assays were obtained from women without breast cancer who underwent reduction breast surgeries. The study was undertaken according to approved institutional review board protocols.

DNA Extraction

Whole 5 micron formalin-fixed tissue sections (5 whole sections) or micro-dissected (10 sections) tumor, normal breast epithelium, benign, and in situ lesions were processed for DNA extraction as previously described [33].

The Methylation-Specific Multiplex Ligation Dependent Probe Amplification (MS-MLPA) Assay

The Multiplex Ligation-Dependent Probe Amplification assay allows for the relative quantification of approximately 41 different DNA sequences in a single reaction requiring only 20 ng of human DNA. The standard use of the technique to observe quantitative changes in copy number [3,34-36] and the adaptation of the MLPA to detect aberrant methylation (MS-MLPA) has been detailed elsewhere [2,14,29,37].

The probe design is similar to ordinary MLPA probes. For 26/41 probes, the recognition sequence detected by the MLPA probe is contained within a restriction site for the methyl-sensitive enzyme, HhaI. The 41 gene probe panel (Table 2) interrogates 35 unique genes implicated in cancer including breast cancer for losses and gains in a separate reaction in the absence of the methyl-sensitive enzyme HhaI.

Table 2.

Methylation-Specific MLPA Probe Panel (ME001).

#	Gene probe	Chrom Loc	#	Gene probe	Chrom Loc	#	Gene probe	Chrom Loc
1	TP73	01p36		CDK6	07q21.3		PAH	12q23
2	CASP8	02q22.3	12	CDKN2A	09p21	21	CHFR	12q24.33
3	VHL	03p25.3	13	CDKN2B	09p21	22	BRCA2	13q12.3
4	RARB	03p24	14	DAPK1	09q34.1		BRCA2	13q12.3
5	*MLH1	03p21.1		AI651963	10p14		MLH3	14q24.3
6	MLH1	03p21.1		CREM	10p12.1		TSC2	16p13.3
	CTNNB1	03p22	15	PTEN	10q23.3		CDH1	16q22.1
7	*RASSF1	03p21.3	16	CD44	11p12	23	CDH13	16q24.2
8	RASSF1	03p21.3	17	GSTP1	11q13	24	HIC1	17p13.3
9	FHIT	03p14.2	18	ATM	11q23	25	BRCA1	17q21
	CASR	03q21	19	IGSF4	11q23		BCL2	18q21.3
10	APC	05q21		TNFRSF1A	12p13		KLK3	19q13
11	ESR1	06q25.1		TNFRSF7	12p13	26	TIMP3	22q12.3
	PARK2	06q26	20	CDKN1B	12q13.1

Bold = probes with HhaI site (n = 26 probes);

genes with multiple probes in the promoter region.

Because there are two probes each for MLH1, RASSF1 and BRCA2, a normal control DNA sample will generate 41 individual peaks in the absence of HhaI (Figure 3A). A concurrently run reaction with the 41 gene probe set in the presence of HhaI is designed to detect aberrant promoter hypermethylation by taking advantage of a HhaI site in the promoter region of 22 of the 35 unique genes (note that one of the two BRCA2 probes is designed to recognize a region outside the HhaI recognition site, Table 2). Fifteen of the 41 gene probes are designed outside a Hha1 site and serve as undigested controls (Figure 3B). Upon digestion of the sample DNA with HhaI, probes that recognize the unmethylated regions will not generate a signal because these sequences have become cut by HhaI and cannot bind to the probe. Conversely, a MLPA probe will bind to an intact methylated site, spared by HhaI, and generate an amplification signal (Figure 1, C-E).

Figure 3.

Normal (control) MS-MLPA assay results of MS-MLPA probe mix without (A) and with (B) HhaI enzyme. Note 15 methylation control peaks in the control DNA sample (B).

Aberrant methylation is identified as the appearance of a signal peak that is otherwise absent in normal DNA samples (Figure 1, C-E). To quantify whether one, both, or more copies of a specific gene locus becomes aberrantly hypermethylated, a previously described mathematical algorithm was employed [2].

Bisulfate Modification and Methylation-Specific Polymerase (MSP) Chain Reaction Assay

For cases with sufficient DNA for bisulfate modification, methylation by MS-MLPA was confirmed by MSP for a limited number of genes (Table 3). Genomic DNA (100ng) from formalin-fixed paraffin embedded breast lesion tissue and control universal methylated DNA (Chamicon International, Inc) and control unmethylated DNA (normal genomic DNA) were modified using the EZ DNA methylation gold kit (Zymo Research, Orange, CA, USA) during which methylated DNA is protected and unmethylated cytosine is converted to uracil [29]. The modified DNA served as a template using primers specific for the methylated or modified unmethylated sequences (Table 3).

Table 3.

Methylation and Unmethylation MSP Primer Sequences for Breast lesions.

Gene	Methylation Specific Primers	Unmethylation Specific Primers	Size
APC-F	5′-TATTGCGGAGTGCGGGTC	5′-GTGTTTTATTGTGGAGTGTGGGTT	M-97 bp
APC-R	5′-TCGAAGAACTCCCGACGA	5′-CCAATCAACAAACTCCCAACAA	U-108 bp
GSTP1-F	5′-TTCGGGGTGTAGCGGTCGTC	5′-GATGTTTGGGGTGTAGTGGTTGTT	M-91 bp
GSTP1-R	5′-GCCCCAATACTAAATCACGACG	5′-CCACCCCAATACTAAATCACAACA	U-97 bp
RASSF1-F	5′-GGGTTTTGCGAGAGCGCG	5′-GGTTTTGTGAGAGTGTGTTTAG	M-169 bp
RASSF1-R	5′-GCTAACAAACGCGAACCG	5′-CACTAACAAACACAAACCAAAC	U-169 bp

F = forward, R = reverse

MSP amplification was performed using 3 μL of bisulfite modified DNA in a final volume of 25 μL PCR mix containing 1× PCR buffer, 2.5 mM dNTP, 1 mM MgCl2 and 1 U Amp gold Taq DNA polymerase, 0.5 μM primer followed by 38 cycles at 95 °C 45 seconds, 62 °C 45 seconds, 72 °C 1 min [29]. The resultant PCR products were separated on 2% agarose gel stained with ethidium bromide and visualized under UV illumination.

Conclusions

In this study, aberrant methylation of RASSF1, APC and GSTP1 were both frequent as well as early events in the progression continuum from normal to benign to invasive cancer and support a monoclonal transformation continuum to breast cancer progression.

Identifying epigenetic alterations in a precancerous lesion may lead to the discovery of biomarkers that add to the knowledge of risk assessment and early detection, and may provide molecular targets for chemopreventive interventions. Because promoter hypermethylation is potentially reversible, molecules that regulate the methylation status of DNA are considered promising targets for new cancer therapies.